ReviewCurrent opinion in HIV and AIDS2016
Role of immune activation in progression to AIDS.
Review in Current opinion in HIV and AIDS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 68 citations in OpenAlex.
- Human umbilical cord mesenchymal stem cell transfusion in immune non-responders with AIDS: a multicenter randomized controlled trial.Signal transduction and targeted therapy · 2021Trial
- Delayed gastrointestinal-associated lymphoid tissue reconstitution in duodenum compared with rectum in HIV-infected patients initiating antiretroviral therapy.AIDS (London, England) · 2019Trial
- Inflammation and Immune Activation in Antiretroviral-Treated Human Immunodeficiency Virus Type 1-Infected African Infants and Rotavirus Vaccine Responses.The Journal of infectious diseases · 2017Trial
- Gut Microbiota Alterations in People Living With HIV: Dysbiosis, Immune Dysfunction and Therapeutic Perspectives.Reviews in medical virology · 2026Review
- Impact of sex differences in adult and paediatric HIV-1 cure.Current opinion in HIV and AIDS · 2026Review
- Increased CD95Frontiers in immunology · 2026Article
- Challenges in the Vaccination of HIV-Infected Individuals.Vaccines · 2025Review
- HIV, Inflammation, and Immunometabolism: A Model of the Inflammatory Theory of Disease.Viruses · 2025Review
- Elevated Levels of Pro-Inflammatory Interleukin-6 in HIV Immunological Non-Responders Among the Indonesian Population.Diagnostics (Basel, Switzerland) · 2025Article
- Heat shock protein 90 is a chaperone regulator of HIV-1 latency.PLoS pathogens · 2025Article
- Multi-omics dissection of metabolic dysregulation associated with immune recovery in people living with HIV-1.Journal of translational medicine · 2025Article
- Patterns of inflammation and immune activation by coreceptor use in people living with HIV-1.Frontiers in immunology · 2025Article
- Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects.Molecules (Basel, Switzerland) · 2024Review
- Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy.The Journal of infectious diseases · 2023Article
- IRAK1 inhibition blocks the HIV-1 RNA mediated pro-inflammatory cytokine response from microglia.The Journal of general virology · 2023Article
- High seroprevalence of Leishmania infantum is linked to immune activation in people with HIV: a two-stage cross-sectional study in Bahia, Brazil.Frontiers in microbiology · 2023Article
- Identification of Potential Diagnostic Genes of HIV-Infected Immunological Non-Responders on Bioinformatics Analysis.Journal of inflammation research · 2023Article
- Naïve B cells with low differentiation improve the immune reconstitution of HIV-infected patients.iScience · 2022Article
- Neuroimmunology of CNS HIV Infection: A Narrative Review.Frontiers in neurology · 2022Review
- Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThe purpose is to review recent insights into the impact of HIV-associated immune activation on AIDS and non-AIDS morbidity and mortality. RECENT
findingsImmune activation has long been recognized as an important consequence of untreated HIV infection and predictor of AIDS progression, which declines but fails to normalize during suppressive antiretroviral therapy, and continues to predict disease in this setting. Thus, a major research agenda is to develop novel therapies to reduce persistent immune activation in treated HIV infection. Yet, the optimal targets for interventions remain unclear. Both the specific root causes of immune activation and the many interconnected pathways of immune activation that are most likely to drive disease risk in HIV-infected individuals remain incompletely characterized, but recent studies have shed new light on these topics. SUMMARY: In the context of this review, we will summarize recent evidence helping to elucidate the immunologic pathways that appear most strongly predictive of infectious and noninfectious morbidity. We will also highlight the likelihood that not all root drivers of immune activation - and the discrete immunologic pathways to which they give rise - are likely to produce the same disease manifestations and/or be equally attenuated by early antiretroviral therapy initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.